Literature DB >> 9224822

Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation.

H Hashimoto1, N Ogawa, N Hagihara, K Yamamoto, K Imanishi, H Nogi, A Nishino, T Fujita, T Matsuda, S Nagata, A Baba.   

Abstract

Vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) receptors are closely related G protein-coupled receptors with seven-transmembrane domains. The VIP receptor can bind both VIP and PACAP with high affinity, whereas the PACAP receptor binds only PACAP with high affinity. To elucidate the structural domains involved in a selectivity for VIP binding and the subsequent receptor activation, a series of chimeric receptors between the VIP and PACAP receptors was constructed, expressed in COS-7 cells, and analyzed for ligand binding and cAMP generation. All chimeric constructs bound PACAP with high affinity and subsequently activated cAMP generation similarly to the wild-type receptors. In contrast, profound differences were observed in the potencies of VIP for competition of 125I-labeled PACAP binding to both wild-type receptors and the chimeric receptors. The cAMP responses of these receptors generally correlated with the ability of VIP to compete for PACAP radioligand binding with the exceptions for some particular chimeras. In this report we demonstrate that several domains, including the amino-terminal extracellular domain, the transmembrane domains I and II, and the first extracellular loop of the VIP receptor, are important for the selectivity for VIP binding and responsiveness to VIP. We further show that the third extracellular loop and its proximal domains of the VIP receptor appear to be involved in the VIP recognition, especially the receptor activation process. On the other hand, the direct binding experiments of the VIP radioligand demonstrated that both wild-type receptors and all chimeric receptors have a high affinity binding site for VIP, although this high affinity VIP binding resulted in a biological response only in the VIP receptor or VIP receptor-like chimeras. This suggests that there is a nonbiologically relevant high affinity VIP-binding site within the rat PACAP receptor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9224822     DOI: 10.1124/mol.52.1.128

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Domains determining agonist selectivity in chimaeric VIP2 (VPAC2)/PACAP (PAC1) receptors.

Authors:  E M Lutz; C J MacKenzie; M Johnson; K West; J A Morrow; A J Harmar; R Mitchell
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

2.  Mapping of the ligand-selective domain of the Xenopus laevis corticotropin-releasing factor receptor 1: implications for the ligand-binding site.

Authors:  F M Dautzenberg; S Wille; R Lohmann; J Spiess
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

3.  Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor.

Authors:  Ingrid Nachtergael; Pascale Vertongen; Ingrid Langer; Jason Perret; Patrick Robberecht; Magali Waelbroeck
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

Review 4.  A new concept in the pharmacology of neuroprotection.

Authors:  I Gozes; D E Brenneman
Journal:  J Mol Neurosci       Date:  2000 Feb-Apr       Impact factor: 3.444

Review 5.  Domain coupling in GPCRs: the engine for induced conformational changes.

Authors:  Hamiyet Unal; Sadashiva S Karnik
Journal:  Trends Pharmacol Sci       Date:  2011-10-29       Impact factor: 14.819

6.  Role of second extracellular loop in the function of human vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide receptor 1 (hVPAC1R).

Authors:  S M Knudsen; J W Tams; J Fahrenkrug
Journal:  J Mol Neurosci       Date:  2000-06       Impact factor: 3.444

7.  Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition.

Authors:  J Van Rampelbergh; M G Juarranz; J Perret; A Bondue; R M Solano; C Delporte; P De Neef; P Robberecht; M Waelbroeck
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.